$Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report$

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report

CONTEXT:Refractory acute myeloid leukemia (AML) is a difficult disease to control with second or third-line chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy.CASE REPORT:52-year-old female was diagnosed with refractory AML and hi...

Full description

Bibliographic Details
Main Authors:	Juliana Todaro, Patrícia Weinschenker Bollmann, Edna Terezinha Rother, Auro del Giglio
Format:	Article
Language:	English
Published:	Associação Paulista de Medicina
Series:	São Paulo Medical Journal
Subjects:	Leukemia, myeloid, acute Drug therapy Abnormal karyotype Angiogenesis inhibitors Azacitidine
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802015000300271&lng=en&tlng=en

Similar Items

Preventive Use of Azacitidine in Patients with Acute Myeloid Leukemia after Haploidentical Allo-BMT
by: RSh Badaev, et al.
Published: (2018-12-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
by: Bingbing Wen, et al.
Published: (2020-03-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis
by: Saveria Capria, et al.
Published: (2013-07-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.
by: Pasquale Niscola
Published: (2014-02-01)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
by: Ritchie EK
Published: (2012-06-01)

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
by: Jiale Ma, et al.
Published: (2021-08-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
by: Akari Hashimoto, et al.
Published: (2014-05-01)

Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia
by: Luka Čemažar, et al.
Published: (2020-12-01)

Indefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia
by: Ali ESER, et al.
Published: (2018-07-01)

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes
by: Michaela Dostalova Merkerova, et al.
Published: (2018-09-01)

Age-specific features of acute myeloid leukemia karyotype
by: Sergey Vasil'evich Gritsaev, et al.
Published: (2011-01-01)

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
by: Claire Horgan, et al.
Published: (2019-02-01)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
by: Sebastian Klobuch, et al.
Published: (2018-11-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

A unique set of complex chromosomal abnormalities in an infant with myeloid leukemia associated with Down syndrome
by: Daiane Correa de Souza, et al.
Published: (2017-09-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-03-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-01-01)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Thomas Cluzeau, et al.
Published: (2019-12-01)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
by: Soichiro Nakako, et al.
Published: (2021-06-01)

Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature
by: Sgherza N, et al.
Published: (2017-06-01)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
by: Lisa Pleyer, et al.
Published: (2017-02-01)

A Rare Cytogenetic Presentation of Acute Myeloid Leukemia (AML-M2)
by: Prasanna Kumari, et al.
Published: (2012-12-01)

A Rare Cytogenetic Presentation of Acute Myeloid Leukemia (AML-M2)
by: Hanumanthappa Vijay Raghavendra, et al.
Published: (2012-12-01)

Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease
by: Koichi Murakami, et al.
Published: (2017-06-01)

Prevalence of 7q deletion in patients with Acute myeloid leukemia .
by: Anjali Shastry1 , Amudha Subramaniam1 , Preetha Tilak2
Published: (2020-08-01)

Genetic Mutations in Acute Myeloid Leukemia
by: OV Blau
Published: (2016-07-01)

Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report
by: Dai Keino, et al.
Published: (2019-11-01)

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
by: Xie CH, et al.
Published: (2018-09-01)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: Jonathan Pan, et al.
Published: (2020-10-01)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
by: Sarah Bertoli, et al.
Published: (2019-07-01)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
by: John F. Seymour, et al.
Published: (2017-12-01)

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
by: Laurène Fenwarth, et al.
Published: (2019-12-01)

Chronic myeloid leukemia: past, present, future
by: Patricia Weinschenker Bollmann, et al.
Published: (2011-06-01)

The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: VN Ovechkina, et al.
Published: (2017-07-01)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
by: Farhad Ravandi, et al.
Published: (2021-08-01)

Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)
by: S V Gritsaev, et al.
Published: (2014-07-01)